Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COPZ1-targeting coatomer inhibitor
- Development stage
- Preclinical
- Lead developer
- Senex Biotechnology
- Modality
- Small Molecules
01
Overview
The COPZ1-targeting coatomer inhibitor is a preclinical small-molecule drug being developed by Senex Biotechnology for the treatment of various cancers. The drug's mechanism of action involves the inhibition of COPZ1 (coatomer protein complex subunit zeta-1), a component of the COPI coatomer complex essential for intracellular vesicle trafficking. The therapeutic rationale is based on a synthetic lethal relationship: while normal cells express both COPZ1 and its paralog COPZ2, many tumor types lose COPZ2 expression, rendering them uniquely dependent on COPZ1 for survival. Unlike many conventional therapies that target only dividing cells, this coatomer inhibitor is designed to kill both proliferating and quiescent tumor cells, potentially leading to more complete tumor eradication.
- Other names
- COPZ1-targeting Coatomer InhibitorCOPZ-1-targeting Coatomer InhibitorCOPZ 1-targeting Coatomer Inhibitorcoatomer inhibitor
Beyond the preview
Go deeper on COPZ1-targeting coatomer inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COPZ1-targeting coatomer inhibitor.